People--Hangzhou Institute of Medicine Chinese Academy of Sciences

Biography

Dr. Xue-Qiang Wang graduated with a master's degree from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2012, and a PhD degree from the Institute of Chemical Research of Catalonia, Spain in 2015. From 2016 to 2017, he engaged in postdoctoral research at the Massachusetts Institute of Technology in the United States. In 2017, he joined the College of Chemistry and Chemical Engineering at Hunan University, Laboratory of Molecular Science and Biomedicine as a professor. In 2023, he moved to Hangzhou Institute of Medicine, Chinese Academy of Sciences as a group leader. He was selected into the 2019 Huxiang Young Talents Program, the 2021 Hunan Province Furong Scholars Award Program-Distinguished Professor, the 2022 Hunan Province Outstanding Youth Project, the 2022 Thieme Chemistry Journals Award, and the 2023 Ministry of Education Young Yangtze Scholars.

Research Interests

Research Interest I: Targeted Drug Delivery

Based on the specific targeting ability of aptamers and the powerful killing ability of small molecule anti-tumor drugs, we are committed to the research topic of aptamer-drug conjugates (ApDC). Our research focus on developing new methods for the precise construction of conjugates, studying the intracellular release mechanism of conjugates, developing new aptamer chemical modification technologies to effectively improve the resistance to enzyme degradation, improving the targeted accumulation ability and deep drug delivery ability in tumor tissue, and enhancing the tumor treatment effect of conjugates in vivo.

Research Interest II: Radionuclide Drug Conjugates

Promoted by the needs in clinical imaging or cancer treatment, we design and construct multivalent recognition ligands using tumor-specific targeting small molecules, peptides, and aptamers, and design new chelating ligands to achieve highly efficient At-211, Pb-212, Lu-177 and Ga-68T labeling under mild conditions. We will also carry out preclinical investigations on radionuclide diagnostic and therapeutic drugs, which mainly includes physical and chemical property assessment, biodistribution research, pharmacodynamics research, pharmacokinetics research, and treatment efficacy of newly developed radionuclide drug conjugates.

Research Interest III: multi-specific aptamers

In this topic, we focus on the development of new methods for constructing multi-specific aptamers to target overexpressed proteins on the tumor cell membranes to achieve collaborative binding, thus greatly improving the recognition accuracy of aptamers against cancer cells. Based on the newly developed molecular recognition tools, we will develop new targeted drug delivery systems, efficient membrane surface protein degradation technologies, and early detection and accurate detection technologies for major diseases such as cancers.

Research Interest IV: New Chemiluminescent Probe Design and Applications.

In this research area, we design and synthesize a series of chemiluminescent probes with a new bicyclic skeleton, allowing us to control the emission wavelength, quantum yield, and other properties of the chemiluminescent probes through structural optimization. By designing of specific response functional groups, it can achieve in vivo detection of enzymes, peptides, ONOO-, H2O2 etc. in vivo. Our goal is to provide novel chemiluminescent probes in the biomedical field for early diagnosis of diseases.

Selected Publications

(1) Chemical Tailoring of Aptamer Glues with Significantly Enhanced Recognition Ability for Targeted Membrane Protein Degradation

Zhang, Guo-Rong; Tan, Weihong; Wang, Xue-Qiang* ACS Nano, 2023, 17, 15146-15154.

(2) Regulating the Properties of XQ-2d for Targeted Therapeutic Agents Delivery to Pancreatic Cancer

Qiuxia Yang, Yongbo Peng, Zhengyu Deng, Dailiang Zhang, Cheng-Yu Long, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*, Weihong Tan* Natl. Sci. Rev., 2023, 10, nwac113.

(3) A Versatile Strategy for Convenient Circular Bivalent Functional Nucleic Acids Construction
Xiao-Jing Zhang, Zhuo Zhao, Xia Wang, Min-Hui Su, Yingying Li, Quan Yuan, Xue-Qiang Wang*, Weihong Tan Natl. Sci. Rev., 2023, 10, nwac107.

(4) Dual‐targeting Circular Aptamer Strategy Enabled Recognition of Different Leukemia Cells with Enhanced Binding Ability

Lili Ai, Tianhuan Peng, Yingying Li, Hailan Kuai, Yingyu Sima, Minhui Su, Dan Wang, Qiuxia Yang, Xue-Qiang Wang*, Weihong Tan Angew. Chem. Int. Ed.2022, 61, e202109500.

(5) A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer

Yingying Li, Y. Peng, Yan Tan, Wenjing Xuan, Ting Fu, Xue-Qiang Wang*, Weihong Tan* Sig. Transduct. Target. Ther.2021, 6, 327.

(6) Regulating the Anticancer Efficacy of Sgc8–Combretastatin A4 Conjugates: A Case of Recognizing the Significance of Linker Chemistry for the Design of Aptamer-Based Targeted Cancer Therapy

Zhiyong Huang, Dan Wang, Cheng-Yu Long, Shen-Huan Li, Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc.2021, 143, 8559–8564.

(7) Molecularly Engineered Aptamers Targeting Tumor Tissue and Cancer Cells for Efficient in vivo Recognition and Enrichment

Xia Wang, Xiao-Jing Zhang, Yingying Li, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*, Weihong Tan CCS Chemistry, 2022, 4, 2581–2587.

(8) Hierarchical Fabrication of DNA Wireframe Nanoarchitectures for Efficient Cancer Imaging and Targeted Therapy

Dan Wang, Ruizi Peng, Yongbo Peng, Zhengyu Deng, Fengyuan Xu, Yuanye Su, Pengfei Wang, Ling Li, Xue-Qiang Wang*, Yonggang Ke*, Weihong Tan* ACS Nano, 2020, 14, 17365-17375.

(9) Highly Chemoselective Access to 2,2'-Diaminobiaryls via Ni-Catalyzed Protecting-Group-Free Coupling of 2-Haloanilines

Cheng-Yu Long#, Shaofei Ni#, Min-Hui Su#, Xue-Qiang Wang*, Weihong Tan ACS Catalysis, 2020, 10, 13641–13649.

(10) Conjugating Aptamer and Mitomycin C with Reductant-Responsive Linker Leading to Synergistically Enhanced Anticancer Effect

Qiuxia Yang, Zhengyu Deng, Dan Wang, Jiaxuan He, Dailiang Zhang, Yan Tan, Tianhuan Peng， Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc.2020, 142, 2532-2540.